Dr. Priyankar Dey

Assistant Professor


Gut microbiota, Chronic metabolic disease, Immunopharmacology.




Gut microbiota, Chronic metabolic disease, Immunopharmacology.



Website: https://priyankardey.weebly.com/



Dr. Dey is trained in immunopharmacology and nutritional biochemistry. His research centers around defining the intestinal-level 3-M interactions between metabolism, microbiome, and metabolome in relation to non-communicable chronic metabolic conditions like obesity, type II diabetes, and nonalcoholic steatohepatitis. In parallel, he is also engaged in applied research to develop prophylactic and therapeutic strategies against chronic metabolic disease, especially by focusing on intestinal and hepatic health (e.g. dysbiosis, gut barrier dysfunction, LPS/TLR4-response). In line, over the years, his research work has deciphered the therapeutic efficacy of several traditional remedies and nutritional supplements. Apart from research, Dr. Dey is currently also engaged in teaching Medical Biotechnology to B.Tech. students.
​'Learning is a continuous process' and 'there is always scope for improvement' are the philosophies of his life. Apart from research and teaching, Dr. Dey takes pleasure in cooking and reading books.


Position and Experience

  • Assistant Professor (01/2020 – Present) Department of Biotechnology, Thapar Institute of Engineering and Technology

  • Senior Research Associate (10/2018 - 11/2019) Bionutrition Core Laboratory, The Ohio State University

  • Post-Doctoral Researcher (8/2016 - 09/2018) Department of Human Sciences, The Ohio State University

  • Senior Research Fellow (project), Indian Council of Medical Research (2/2014 - 10/2015) Department of Zoology, University of North Bengal

  • Senior Research Fellow (DBT) (6/2013 - 2/2014) Department of Zoology, University of North Bengal

  • Junior Research Fellow (DBT) (6/2011 - 6/2013) Department of Zoology, University of North Bengal

  • Visiting Scholar (Intermittent) (1/2014 -1/2016) Department of Botany, University of Calcutta

  • Visiting Scholar (Intermittent) (8/2011 - 2/2012) Department of Molecular Medicine, Bose Institute


Recent Publications

  • Priyankar Dey, Saumya Ray Chaudhuri. The opportunistic nature of gut commensal microbiota. Critical Reviews in Microbiology (2022). Accepted. IF: 7.391

  • Xiaowei Sun, Priyankar Dey, Richard S. Bruno, Jiangjiang (Chris) Zhu. EGCG and Catechin Relative to Green Tea Extract Differentially Modulate the Gut Microbial Metabolome and Liver Metabolome to Prevent Obesity In Mice Fed A High-Fat Diet. Journal of Nutritional Biochemistry (2022). IF: 6.117

  • Jalal Moludi; Ebrahim Shakiba; Mehdi Moradinazar; Yahya Pasdar; Negin Kamari; Farid Najafi; Behrooz Hamzeh; leile sheikhi; Priyankar Dey. Association of Dietary Inflammatory Index with Renal Function and Kidney Stones in Iranian Kurdish Adults: Results from RaNCD Cohort Study. Frontiers in Nutrition (2022, Accepted). IF: 6.590

  • Priyankar Dey, Saumya Ray Chaudhuri. Cancer-associated microbiota: from mechanisms of disease causation to microbiota-centric anti-cancer approaches. Biology 2022. 11(5): 757. IF: 5.168

  • Sisi Cao, Emily L Shaw, William R Quarles, Geoff Y Sasaki, Priyankar Dey, Joanna K Hodges, Avinash Pokala, Min Zeng, Richard S Bruno. Daily inclusion of potatoes in a Dietary Guidelines for Americans dietary pattern does not adversely affect cardiometabolic risk in adults with metabolic syndrome: a randomized controlled trial. Nutrients 2022. 14 (8), 1545. IF: 6.706

  • Priyankar Dey*, Saumya Ray Chaudhuri, Thomas Efferth, Sirshendu Pal. The intestinal 3-M (microbiota, metabolism, metabolome) zeitgeist – from fundamentals to future challenges. Free Radical Biology & Medicine 2021. 176(11): 265-285. IF. 8.101

  • Manas Ranjan Saha, Priyankar Dey. Pharmacological benefits of Acacia against metabolic disease: Intestinal-level bioactivities and favorable modulation of gut microbiota. Archives of Physiology and Biochemistry (online ahead of print). IF: 3.188

  • Jalal Moludi, Arash Tandorost, Hamed Jafari-Vayghyan, Priyankar Dey. Dietary inflammatory index (DII) in relation to psoriasis risk, cardiovascular risk factors, and clinical outcomes; a result from a case-control study in psoriasis patients. Applied Physiology, Nutrition, and Metabolism. 46(12):1517-1524. IF: 3.016

  • Manoj Baranwal, Yogita Gupta, Priyankar Dey*, Suktilang Majaw. Anti-inflammatory phytochemicals as prophylaxis in viral infection: scope, rationale, application, and limitations. Phytotherapy Research 2021. 35(11): 6148-6169. IF: 6.388

  • Matthew Goodus, Kaitlin Carson, Andrew Sauerbeck, Priyankar Dey, Anthony Alfredo, Phillip Popovich, Richard Bruno, and Dana McTigue. Liver inflammation enhances neuropathology, liver injury, metabolic syndrome and motor deficits after spinal cord injury. Experimental Neurology 2021. 342(8): 113725. IF: 5.62

  • Priyankar Dey. Low bioavailability hinders in silico docking-guided drug discovery against COVID-19. British Journal of Pharmacology 2021. 178(3): 741-742. IF: 9.473.

  • Haley Chatelaine, Priyankar Dey, Xiaokui Mo, Eunice Mah, Richard S. Bruno, Rachel E. Kopec. Vitamin A and D absorption in adults with metabolic syndrome vs. healthy controls – a pilot study utilizing targeted and untargeted LC-MS lipidomics. Molecular Nutrition and Food Research 2021. 65(2):2000413. IF: 6.575.


Recent Research Grants

  • An artificial colon model for microbiota research (AMMR). BIRAC (PI). 2022

  • Development of gut microbiota-resistant mucoadhesive bio-nano-encapsulation for efficient delivery of epigallocatechin gallate isolated from endophytic fungi of Camelia sinensis (tea). SERB-POWER grant (co-PI) 2022.

  • Identification of immunogenic peptide for diagnosis of orthohantavirus infection. DST Indo-Russia (co-PI) 2022.

  • Development of an in vitro pseudo-facilitation model of lipotoxicity in NAFLD-associated metainflammation coupled with characterization of hepatocellular global metabolomic signatures. SERB-SRG 2021.

  • Gut microbiome-resistant chitosan-EGCG nanoconjugates for efficient intracellular redox homeostasis and maintenance of global metabolome. Bio-X initiative under TIET- Virginia Tech Center of Excellence for Emerging Materials (PI) 2021.

  • Development of Nano-bio-composites as next generation arsenal against biofilms. TIET- Virginia Tech Center of Excellence for Emerging Materials (co-PI) 2020.

  • Development of commensal gut microbes-derived non-immunogenic therapeutic leads through identification and evaluation of intestinal targets against chronic metabolic disease. TIET seed grant (PI) 2020.

Last updated on 20.07.2021

Download Brochure